Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite, effective as of November 15, 2022. These leadership moves reflect the company’s strategic focus on growth and operational excellence.
CFO Promotion
Ye Yongji, former China Chief Financial Officer (CFO), has been promoted to group CFO, vice-president of corporate financial affairs, and CFO of the subsidiary RNAimune. Mr. Ye joined Sirnaomics in October 2018, bringing over 14 years of experience in strategic planning, financial analysis, management, mergers and acquisitions, private equity investment, corporate financing, and internal control. He has held significant positions at KPMG, Rocher (Hong Kong), Credit Suisse (Hong Kong), and other leading firms.
CEO Promotion
Zhang Yun, former China Chief Operation Officer (COO), has been promoted to group China Chief Executive Officer (CEO), secretary of the board of directors, secretary of the joint company, and general manager of the subsidiary Shengnuo Meike Biomedical Technology (Beijing) Co., Ltd. She joined Sirnaomics in November 2015, with over 14 years of international experience in strategic management, enterprise financing, internal operations, marketing, business expansion, and corporate governance. She previously served as a project manager at the National Foundation for Cancer Research (NFCR) in Maryland, USA.
Future Implications
These executive promotions underscore Sirnaomics’ commitment to strengthening its leadership team with seasoned professionals. The company aims to leverage the expertise of Mr. Ye and Ms. Zhang to drive strategic growth initiatives and enhance operational efficiency, positioning Sirnaomics for continued success in the global siRNA therapy market.-Fineline Info & Tech
